Recro Pharma, Inc. 4
4 · Recro Pharma, Inc. · Filed Dec 5, 2016
Insider Transaction Report
Form 4
Mack Randall
Senior VP, Development
Transactions
- Exercise/Conversion
Common Stock
2016-12-01+6,100→ 11,654 total - Tax Payment
Common Stock
2016-12-01$6.48/sh−1,892$12,260→ 9,762 total
Footnotes (1)
- [F1]On December 1, 2016, the Compensation Committee of the Board of Directors of the Issuer determined that performance-vesting criteria were met with regard to 6,100 performance-based restricted stock units, which were converted into 6,100 shares of common stock on a one-for-one basis.